Impact of immature platelets on platelet response to ticagrelor and prasugrel in patients with acute coronary syndrome

European Heart Journal

Volumn 36, Issue 45, 2015, Pages 3202-3210

  Bernlochner, Isabell ^a   Goedel, Alexander ^a   Plischke, Conny ^a   Schupke, Stefanie ^b,c   Haller, Bernhard ^d   Schulz, Christoph ^b   Mayer, Katharina ^b   Morath, Tanja ^b   Braun, Siegmund ^b   Schunkert, Heribert ^b,c   Siess, Wolfgang ^e   Kastrati, Adnan ^b,c   Laugwitz, Karl Ludwig ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Reticulated platelets Platelet aggregation Ticagrelor Prasugrel Acute coronary syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; PADGEM PROTEIN; PRASUGREL; THIAZOLE ORANGE; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; AUTOMATION; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; FEMALE; HEMATOLOGICAL PARAMETERS; HEMATOLOGY ANALYZER; HOSPITAL ADMISSION; HUMAN; IMMATURE PLATELET FRACTION; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MULTICENTER STUDY; MULTIPLE ELECTRODE AGGREGOMETRY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; HOSPITALIZATION; METABOLISM; THROMBOCYTE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ADENOSINE; AGED; BLOOD PLATELETS; FEMALE; HOSPITALIZATION; HUMANS; MALE; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; TREATMENT OUTCOME;

EID: 84983142541     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv326     Document Type: Article

References (36)

1. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541-2619.
2. Bonello L, Pansieri M, Mancini J, Bonello R, Maillard L, Barnay P, Rossi P, Ait-Mokhtar O, Jouve B, Collet F, Peyre JP, Wittenberg O, de Labriolle A, Camilleri E, Cheneau E, Cabassome E, Dignat-George F, Camoin-Jau L, Paganelli F. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 2011;58:467-473.
3. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schomig A, Kastrati A, von Beckerath N. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009;53:849-856.
4. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 2013;382:614-623.
5. Bernlochner I, Sibbing D. Thienopyridines and other ADP-receptor antagonists. Handb Exp Pharmacol 2012;210:165-198.
6. Thon JN, Italiano JE Jr. Does size matter in platelet production? Blood 2012;120: 1552-1561.
7. Denis MM, Tolley ND, Bunting M, Schwertz H, Jiang H, Lindemann S, Yost CC, Rubner FJ, Albertine KH, Swoboda KJ, Fratto CM, Tolley E, Kraiss LW, McIntyre TM, Zimmerman GA, Weyrich AS. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets. Cell 2005;122:379-391.
8. McBane RD II, Gonzalez C, Hodge DO, Wysokinski WE. Propensity for young reticulated platelet recruitment into arterial thrombi. J Thromb Thrombolysis 2014; 37:148-154.
9. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034-2045.
10. Zanazzi M, Cesari F, Rosso G, Farsetti S, Caroti L, Gori AM, Cerini G, Cioni G, Bertoni E, Abbate R, Salvadori M. Reticulated platelets and platelet reactivity in renal transplant recipients receiving antiplatelet therapy. Transplant Proc 2010;42:1156-1157.
11. Lakkis N, Dokainish H, Abuzahra M, Tsyboulev V, Jorgensen J, De Leon AP, Saleem A. Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol 2004;44:2091-2093.
12. Grove EL, Hvas AM, Kristensen SD. Immature platelets in patients with acute coronary syndromes. Thromb Haemost 2009;101:151-156.
13. Perl L, Lerman-Shivek H, Rechavia E, Vaduganathan M, Leshem-Lev D, Zemer-Wassercug N, Dadush O, Codner P, Bental T, Battler A, Kornowski R, Lev EI. Response to prasugrel and levels of circulating reticulated platelets in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol 2014; 63:513-517.
14. Cesari F, Marcucci R, Caporale R, Paniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Hae-most 2008;99:930-935.
15. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, DeLao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008;52:743-749.
16. Ibrahim H, Nadipalli S, DeLao T, Guthikonda S, Kleiman NS. Immature platelet fraction (IPF) determined with an automated method predicts clopidogrel hypore-sponsiveness. J Thromb Thrombolysis 2012;33:137-142.
17. Grove EL, Wurtz M, Hvas AM, Kristensen SD. Increased platelet turnover in patients with previous definite stent thrombosis. J Thromb Haemost 2011;9: 1418-1419.
18. Cesari F, Marcucci R, Gori AM, Caporale R, Fanelli A, Casola G, Balzi D, Barchielli A, Valente S, Giglioli C, Gensini GF, Abbate R. Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost 2013;109:846-853.
19. Ibrahim H, Schutt RC, Hannawi B, DeLao T, Barker CM, Kleiman NS. Association of immature platelets with adverse cardiovascular outcomes. J Am Coll Cardiol 2014; 64:2122-2129.
20. Hoffmann JJ. Reticulated platelets: analytical aspects and clinical utility. Clin Chem Lab Med 2014;52:1107-1117.
21. Schulz S, Angiolillo DJ, Antoniucci D, Bernlochner I, Hamm C, Jaitner J, Laugwitz KL, Mayer K, von Merzljak B, Morath T, Neumann FJ, Richardt G, Ruf J, Schomig G, Schuhlen H, Schunkert H, Kastrati A. randomized comparison of ticagrelor versus prasu-grel in patients with acute coronary syndrome and planned invasive strategy-design and rationale of the intracoronary stenting and antithrombotic regimen: rapid early action for coronary treatment (ISAR-REACT) 5 trial. J Cardiovasc Transl Res 2014;7:91-100.
22. Penz SM, Bernlochner I, Toth O, Lorenz R, Calatzis A, Siess W. Selective and rapid monitoring of dual platelet inhibition by aspirin and P2Y12 antagonists by using multiple electrode aggregometry. Thromb J 2010;8:9.
23. Diedenhofen B. Comparing correlations (version 1. 0-0). http://r.birkdiedenhofen. de/pckg/cocor/2013 (accessed 10 October 2014).
24. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, Gachet C, Montalescot G, Jennings LK, Kereiakes D, Sibbing D, Trenk D, Van Werkum JW, Paganelli F, Price MJ, Waksman R, Gurbel PA. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56:919-933.
25. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-1057.
26. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
27. Bonello L, Frere C, Paganelli F, Laine M. With age comes wisdom: is this true for platelets? J Am Coll Cardiol 2014;63:518-519.
28. Farid NA, Smith RL, Gillespie TA, Rash TJ, Blair PE, Kurihara A, Goldberg MJ. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab Dispos 2007; 35:1096-1104.
29. Scharbert G, Wetzel L, Schrottmaier WC, Kral JB, Weber T, Assinger A. Comparison of patient intake of ticagrelor, prasugrel, or clopidogrel on restoring platelet function by donor platelets. Transfusion 2015;55:1320-1326.
30. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mel-litus and micro-or macrovascular complications. Thromb Haemost 2011;106:491-499.
31. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morosetti R, Mirabella M, Ghirlanda G, Davi G, Patrono C. The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. J Thromb Haemost 2012;10:1220-1230.
32. Pascale S, Petrucci G, Dragani A, Habib A, Zaccardi F, Pagliaccia F, Pocaterra D, Ragazzoni E, Rolandi G, Rocca B, Patrono C. Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood 2012;119:3595-3603.
33. van Giezen JJ, Nilsson L, Berntsson P, Wissing BM, Giordanetto F, Tomlinson W, Greasley PJ. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J Thromb Hae-most 2009;7:1556-1565.
34. Teng R, Oliver S, Hayes MA, Butler K. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos 2010;38:1514-1521.
35. Godier A, Taylor G, Gaussem P. Inefficacy of platelet transfusion to reverse ticagre-lor. N Engl J Med 2015;372:196-197.
36. Kuijpers MJ, Megens RT, Nikookhesal E, Feijge MA, De Mey JG, oude Egbrink MG, van Giezen JJ, Heemskerk JW. Role of newly formed platelets in thrombus formation in rat after clopidogrel treatment: comparison to the reversible binding P2Y(1)(2) antagonist ticagrelor. Thromb Haemost 2011;106: 1179-1188.